drugset / Trial / NCT06017895

Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma

NCT06017895

RandomizedCrossoverDouble-blindSupportive care

Summary

The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for nasopharyngeal carcinoma.

Timeline

Start
2023-10-31
Primary completion
2026-07-31
Completion
2026-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxepin Unknown 2 ml Other

Indications

No indication recorded.